New insider activity at NKGen Biotech ( (NKGN) ) has taken place on June 2, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Significant shareholder CFIC-2015 NV Family Investments, LLC has made a notable acquisition by purchasing 19,669,552 shares of NKGen Biotech stock, valued at $2,360,346.
Recent Updates on NKGN stock
NKGen Biotech has recently made several strategic financial moves, including entering into a Stock Purchase Agreement with CFIC-2015 NV Family Investments, LLC to raise $2.5 million through the sale of common stock and warrants. Additionally, CEO Paul Y. Song has personally invested $2.65 million to support the company’s Phase 2 clinical trial for Alzheimer’s Disease and to manage financial obligations. These actions reflect confidence in the company’s potential and aim to strengthen its capital structure. However, NKGen has announced a delay in filing its Form 10-Q due to additional time needed for valuation and review of derivative securities, though it does not expect significant changes in financial results. The company’s technical sentiment signal remains ‘Sell’, with a current market cap of $13.03 million.
More about NKGen Biotech
YTD Price Performance: -59.13%
Average Trading Volume: 378,027
Technical Sentiment Signal: Sell
Current Market Cap: $12.68M